bluebird (BLUE) Up as FDA Nod Likely for Thalassemia Therapy - June 8, 2022 - Zacks.com
48,724 Shares in bluebird bio, Inc. (NASDAQ:BLUE) Purchased by Inspire Investing LLC - Defense World
Patient Flips — $DHI - 10.2.2017 entry analysis Setup: Change of...
Bluebird Prices New Shares At $55, Seeks To Raise $500 Million
ARKG: Don't Always Follow The Leader (BATS:ARKG) | Seeking Alpha
BPC Academy: Intro to Biotech Trading • BioPharmCatalyst
bluebird (BLUE) Gene Therapies BLA Decision Delayed, Stock Down - January 19, 2022 - Zacks.com
VCEL Stock Forecast, Price & News (Vericel)
EXTN Stock Forecast, Price & News (Exterran)
Deep dive writeup: $ASTS <> AST SpaceMobile
Arena, Harley-Davidson, Bluebird Bio, Peloton: What to Watch When the Stock Market Opens Today - Stockxpo - Grow more with Investors, Traders, Analyst and Research
bluebird (BLUE) Q2 Loss Narrower Than Expected, Sales Miss - August 5, 2022 - Zacks.com
bluebird bio Sinks 48% on Muted Q3 Results
Don't Go Bargain Hunting on Bluebird Bio Stock, Says Analyst
BPC Academy: Intro to Biotech Trading • BioPharmCatalyst
bluebird bio May Need to Raise Cash Soon
Teodoro Gris (@TeodoroGris) / Twitter
bluebird bio, Inc. (NASDAQ:BLUE) Receives Consensus Rating of "Hold" from Analysts | MarketBeat
Why bluebird bio (BLUE) Stock Plunged 60% Year to Date? - April 22, 2022 - Zacks.com
ADAP Stock Forecast, Price & News (Adaptimmune Therapeutics)
Bluebird Reports Disappointing Q2 Results; Shares Plunge 27.5%
SESN Stock Forecast, Price & News (Sesen Bio)
bluebird bio to Resume Marketing of ZYNTEGLO in EU
